-- Days : -- HRS : -- MIN : -- SEC

Register Now →

News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Thomas J. Bramley, PhD

Articles by Thomas J. Bramley, PhD

Disease Progression and the Need for Neuroprotection in Glaucoma Management

ByRohit Varma, MD,Patti Peeples, RPh, PhD,John G.Walt, MBA,Thomas J. Bramley, PhD

February 15th 2008

Current Management of Glaucoma and the Need for Complete Therapy

ByStuart J. McKinnon, MD, PhD,Lawrence D. Goldberg, MD,Patti Peeples, RPh, PhD,John G.Walt, MBA,Thomas J. Bramley, PhD

February 15th 2008

Managed Care and the Impact of Glaucoma

ByClaiborne E. Reeder, RPh, PhD,Meg Franklin, PharmD, PhD,Thomas J. Bramley, PhD

February 15th 2008

Circadian Rhythmicity and the Pharmacologic Management of Insomnia

ByGary S. Richardson, MD,Beatriz Manzor Mitrzyk, PharmD,Thomas J. Bramley, PhD

November 1st 2007

The State of Insomnia and Emerging Trends

ByThomas Roth, PhD,Meg Franklin, PharmD, PhD,Thomas J. Bramley, PhD

November 1st 2007

Chronic Insomnia Treatment and Medicare Part D: Implications for Managed Care Organizations

ByRobert Navarro, PharmD,Beatriz Manzor Mitrzyk, PharmD,Thomas J. Bramley, PhD

November 1st 2007

Current Landscape of Insomnia in Managed Care

ByClaiborne E. Reeder, RPh, PhD,Meg Franklin, PharmD, PhD,Thomas J. Bramley, PhD

November 1st 2007

Latest Updated Articles

Disease Progression and the Need for Neuroprotection in Glaucoma Management
February 15th 2008
Current Management of Glaucoma and the Need for Complete Therapy
February 15th 2008
Managed Care and the Impact of Glaucoma
February 15th 2008
Circadian Rhythmicity and the Pharmacologic Management of Insomnia
November 1st 2007
The State of Insomnia and Emerging Trends
November 1st 2007
Chronic Insomnia Treatment and Medicare Part D: Implications for Managed Care Organizations
November 1st 2007

Trending on AJMC

FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success

CANN Responds to HRSA's Revised 340B Rebate Model Pilot

Infection Remains a Major Burden in Blood Cancers

Lilly Expands Retatrutide Access Amid Doctor Pushback

Setting Treatment Goals in RA: Remission, Joint Damage, and Systemic Risk